Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Henry Schein Inc. (HSIC - Analyst Report) recently extended its long-standing relationship with Masimo Corporation (MASI - Analyst Report) through another distribution agreement. Henry Schein’s animal health business in the U.S. – Butler Schein Animal Health will now distribute Masimo’s innovative portfolio of pulse oximetry technologies.

This appears to be a lucrative deal for Henry Schein as it will expand its product offering for the fast growing animal health market. Revenues from the animal health business recorded robust double-digit growth for the fifth straight quarter in the first quarter of 2013. The inclusion of Masimo’s advanced pulse oximetry technology should accelerate growth for Henry Schein’s animal health franchise.

Henry Schein continues to capture share in the animal health market. Following the deal, Masimo’s innovative portfolio will be made available to Butler Schein’s customer base of over 26,000 veterinary professionals across the U.S. The novel distribution agreement with Masimo should further expand Henry Schein’s market reach.

The distribution agreement applies to Masimo’s upgradable rainbow Radical-7 Pulse CO-Oximeters, Rad-87, Rad-57, Rad-5 and Rad-8, all with SET Measure-Through Motion and Low Perfusion pulse onximetry. The deal between Masimo and Henry Schein intends to leverage the companies’ revenue profile.

At present, Henry Schein is rebranding Butler Schein Animal Health to Henry Schein Animal Health and expects to complete the procedure in the ongoing year. The rebranding of domestic operations coupled with international network in Europe, Australia and Asia is likely to strengthen Henry Schein’s global foothold in the animal health market.

While Henry Schein continues to boost its domestic animal health business, unfavorable macroeconomic factors in the overseas market such as currency headwinds and touch capital spending environment remain an overhang. The stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for Henry Schein, we are positive that Steris Corp. (STE - Snapshot Report) and CONMED Corporation (CNMD - Analyst Report), carrying a Zacks Rank #2 (Buy) will do well.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%